Peripheral Artery Disease: Underestimated and Undertreated

Compared against coronary artery disease (CAD) or cerebrovascular disease patients, peripheral artery disease (PAD) patients have lower chances of receiving medication proved to be clinically effective such as statins (despite running the same risk, perhaps even higher risk). 

Enfermedad vascular periférica subestimada y subtratada

The message is we should be more active both in finding risk factors in PAD patients, and in finding PAD in CAD and cerebrovascular patients. 

Claudication symptoms can be underestimated by both patients and doctors when patients consult for a recent myocardial infarction. Likewise, claudication symptoms can be limiting enough to prevent angina from happening. 

This study, including roughly a million patients, was recently published in the Journal of the American College of Cardiology.

Over half of CAD patients (51.7%) were on statins vs 43% who had cerebrovascular disease, and only 33.9% who had PAD. 


Read also: Consensus on How to Conduct Follow-Up in Peripheral Vascular Disease.


And of those with a confirmed diagnostic of the three concurrent conditions, only 57% received statins. 

This study speaks of inadequate treatment according to the clinical practice guidelines, across all the vascular disease spectrum, and not just PAD. 

CAD patients were the ones who presented more events. However, PAD and cerebrovascular patients showed higher all-cause mortality rate. 


Read also: Safety of Paclitaxel-Coated Balloons in Peripheral Vascular Disease.


There are still many wasted opportunities, particularly in PAD patients, but in all patients in general. 

Original Title: Atherosclerotic risk and statin use among patients with peripheral artery disease.

Reference: Colantonio LD et al. J Am Coll Cardiol. 2020;76:251-264.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....